Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica Plc LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Shares Traded Last Trade
  -10.50 -2.94% 346.50 109,599 16:35:07
Bid Price Offer Price High Price Low Price Open Price
345.50 349.50 355.50 339.00 350.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 142.80 19.88 22.77 15.2 333
Last Trade Time Trade Type Trade Size Trade Price Currency
18:10:11 O 150 342.88 GBX

Oxford Biomedica (OXB) Latest News

More Oxford Biomedica News
Oxford Biomedica Investors    Oxford Biomedica Takeover Rumours

Oxford Biomedica (OXB) Discussions and Chat

Oxford Biomedica Forums and Chat

Date Time Title Posts
01/10/202204:17Where we going226
30/9/202220:45OXB. One owner, FSH Excellent conditionwith ejector seat3,970
29/9/202209:55OXB - sense and sensibility432
22/9/202218:38Open-minded posters thread571
22/9/202215:54Oxford Biomedica2,098

Add a New Thread

Oxford Biomedica (OXB) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Oxford Biomedica trades in real-time

Oxford Biomedica (OXB) Top Chat Posts

Top Posts
Posted at 01/10/2022 09:20 by Oxford Biomedica Daily Update
Oxford Biomedica Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OXB. The last closing price for Oxford Biomedica was 357p.
Oxford Biomedica Plc has a 4 week average price of 339p and a 12 week average price of 339p.
The 1 year high share price is 1,606p while the 1 year low share price is currently 339p.
There are currently 96,062,640 shares in issue and the average daily traded volume is 178,258 shares. The market capitalisation of Oxford Biomedica Plc is £332,857,047.60.
Posted at 18/9/2022 09:31 by badger60
Fwiw...if you want to witness gross ineptitude look no further than the OXB management, and especially the forward share price guestimates which were recently submitted by Harry's "loyal" OXB shareholders. Much as I can appreciate that many are philanthropic in their hearts, the share price reality has turned out to be the complete opposite of expectations. In the meantime the inept management are awarding themselves share options and enjoying a fantastic unfettered life style.......at your expense....for as long as it lasts!!
Posted at 17/9/2022 09:49 by badger60
Oh please!!!! Why do some posters still refer to the one and only time that OXB actually made a material profit......AZN Vax manufacturing. Those days are long gone and only serve to highlight the dire financial position that OXB finds itself, with an emphasis on the inept management decision at the time to recklessly buy into the Hemology " dream" and create a 200 Mio quid millstone around OXB's US/UK head which includes a 70 Mio loan due next March. In the meantime the Homology cashburn has been nearly 60 Mio USD since January to June this year. ......and that's the good news.......Both UK and US revenues have been a pittance, arguably with more third party losses than gains. OXB/ Homology in house product development has been an ongoing waste of money with no meaningful revenue contribution added to the bottom line. OXB is well and truly between a rock and a very hard place. No new lucrative third party contracts, but development work which burns huge amounts of cash....which is going nowhere fast. Already cutbacks in staff, and the proposed leaseback of property is the order of the day. Homology got all their birthdays in one hit....cash up front and business as usual at OXB's expense . Imo the OXB group is destined for the skip........maybe sooner rather than later............
Posted at 16/9/2022 09:11 by gigabit
One of the interesting features of the OXB share price is its volatility. The company has a high proportion of shares owned by long-term holders and they do not impact on the share price at all as they neither buy nor sell. So the number of shares available to short-term investors is small and therefore relatively small trades have a disproportionate impact. The LTHs have bought in with their hearts, quite justifiably feeling they want to support a company that brings great benefits to humanity. STHs, including me, buy in with their heads and are looking to gain which is perfectly justifiable too especially when you throw in the feel-good factor as well. OXB will always be a volatile share. Joe may well be right, on a 5 to 10 year time-scale.
Posted at 15/9/2022 11:36 by harry s truman
Quick update on my running wish list to reflect the new AAV deal yesterday and what was said about Serum in the RNS this morning:- 1) News from AZ re covid vaccine (Roch said when not if) - DELIVERED 1st July 2022. 2) More LV deals for Oxford - DELIVERED (BMS deal expanded 21st July 2022). DELIVERED (new deal with up-front payment, confidential partner 26th July 2022). DELIVERED (new deal with up-front payment, confidential partner 7th September 2022). 3) New AAV deals for Boston (2 promised before year end by Roch at the full year results / Update - reiterated 16/08/2022). DELIVERED 1st new AAV development and supply contract 14th Sept 2022. 4) Whatever Serum are planning under this Memorandum of understanding signed with OXB about building their footprint in the UK as mentioned by Stuart? (We can probably guess vaccine work in OxBox but they need to say). UPDATE 13th August boss of SII says in press interview that OxBox can be used for vaccine work. UPDATE 15th September OXB confirm Serum has right of first refusal to the exclusive use of an under construction 2,000L bioreactor in the 2nd half of Oxbox. Exclusive use will require Serum Life Sciences to commit to a minimum contract value per year for up to ten years. 5) OXB / Novartis RNS (re need for more vector for CAR-T after approval in FL would be nice). 6) Partner the in-house CAR-T drug - OXB-302 Acute Myeloid Leukaemia (they are preparing for clinical trial which Roch said we are NOT! going to do ourselves so surely they must have somebody lined up). 7) Partner something re in vivo CAR-T (is this basically T-Charge?) / confirmation from Novartis that their T-Charge program uses Lentivector. 8) One of our liver drugs partnered OXB-40X/Y/Z (early stage but somebody might want to licence). 9) News from any of our partners who are in the clinic with our tech (vague I realise but you never know as we have a lot of partners). DELIVERED (Orchard deal for LentiStable 26th July 2022). 10) Relicense the PD drug as they say they have 2 companies waiting for the legal end with Sio (I'm think this won't be quick, but you never know).
Posted at 15/9/2022 10:10 by seanje
Unfortunately OXB right now is just one very unloved stock and that is not going to change until such time the sentiment swings in the other direction and there is no way of predicting when that will be. I have seen it so many times before snd the unpredictability is just so predictable. The OXB business is complex but I believe it has a more than better chance of rapidly getting back to where it was and the possibility of doing something truly exceptional. Which is why I am sitting right, for however long it takes. Of course there is a wild card here and that is OXB gets asked by SII to manufacture the malaria vaccine once it gets regulatory approval and that could be very soon. We don't know how much money OXB would get out of that, but I am guessing that, like the Vovid vaccine it would send the share price racing. All to play for IMO and a solid set of results.
Posted at 12/9/2022 09:33 by gigabit
The statement by Dave Backer, a few weeks ago now, is rather odd. He is the OXB Chief Commercial Officer so should know the impact of what he says. He stated that OXB had bought a majority stake in Homology. That is totally contrary to the announcement at the finals presentation where it was said that OXB had entered into a JV with Homology and owned 80% of the new entity, not a stake in Homology itself. This really matters. If OXB does own most of Homology that could be disastrous in that Homology is heavily loss-making and projects to remain so for the foreseeable future. The JV, on the other hand and subject to it getting some contracts, has some hope of becoming profitable in due course. I doubt that his statement has done the prospects of the share price any good.
Posted at 03/9/2022 10:28 by harry s truman
A lot of life is just pure luck ibby. I realise that is the easy excuse for mediocrity with anything / anybody, but I particularly enjoy reading memoires / autobiographies / biographies of people who I've liked or admired and somewhere along the line there's usually the common theme of some good fortune which was absolutely out of their control. The decent people in life are often the first to admit that. I can definitely recall a couple of different times where pivotal news for OXB has occurred during the Christmas holidays - and when a company's shareholders have waited patiently for that news, to see it come at the worst possible time for market impact (through no fault of OXB) is one of those situations where you just have to eat it and move on. I honestly don't know what I think about the Ukraine, other than it being a tragedy of course. It seems to me with hindsight that when Biden said very early this year that there would be limited consequences if Putin kept his action mainly to the Russian speaking areas, it was to tempt him into doing exactly that and he fell for it. I might be into tinfoil hat territory there, and of course it's unthinkable for us to consider that someone would use an entire population of people as pawns, but since the invasion how many politicians (any country) have you heard apportioning the current economic / financial situation to the coronavirus lockdown and spending? But this is primarily an OXB thread, and over the years the main themes peddled by critics have been money worries (in the past often justified) and the better mousetrap potentially being developed elsewhere (just part of life in biotech). There really isn't a lot else apart from grudges and egos leading to glee when the price is going in the preferred direction. QED, for the patient (and most of us here have black belts in that) it will eventually be ok. We have a large chunk of the LV market and the ability to make it. As of this year we have a smaller chunk of a much larger AAV market and the ability to make it, and of course we proved ourselves to the world with the AV work on the coronavirus vaccine for which we are still being punished. OXB really does have a lot going for it and if any other share has suffered the beating on best ever full year results which OXB did this year, then I've never heard of it. Unfortunately though, this type of thing does happen and if it didn't then none of us would ever be able to buy anything at a discount - for instance profitable yield shares where intuition tells you that there must be something wrong, but there isn't. Healthcare / life science is a better sector than most to ride out a recession in. I'm expecting quite a few small development deals with OXB, but there is potential here for something much larger - likely with one of our existing huge pharma company partners. If that happens then it will be on their timescale, but there are signs and clues in what OXB have already said. In the last sweep then almost everybody got it badly wrong as I don't think anybody honestly expected such a bad reaction to record high figures, but often our sweep winners have pretty much dropped in the "sensible middle" of the spread. Based on that I'd say that nudging £5 is looking good, so you may well be in the winners circle, but of course we have 8 potential news days before the results day decides the winner.
Posted at 02/9/2022 22:30 by ibby5
Harry I think we have come a long way since I suspect you and I first purchased into oxb, from a penny share company to entering the FTS 250 although we are temporary out at the moment. Also we have managed to enter the American market and that might prove to be a great achievement. Like you said Harry the Russian conflict has effected every big and small company not just oxb, even the £ has collapsed against the $ hopefully that might help us out when it comes to the exchange rate with our American business. My personal view is that until the Russian Ukrainian conflict comes to a conclusion than I can't see any big movement in our share price or come to think of it in any other company's share price. The winner takes it all for those have the courage to invest now at the bottom of this market unfortunately I have no more money left to invest otherwise I would have. Well Harry you once told me to get involved on this thread this was a while back under my old name of ABD but as I have so many different password's I quickly seem to forget them all and I can't log in as in this case, perhaps I should have made a list of them in my diary. If I win this sweep I am going to donate my price to my old mate bordger.
Posted at 01/9/2022 20:23 by harry s truman
Dom, Gigabit is probably unaware of rule 3b, which states that people who have been filtered by me for enjoying the price slide just a little too much will find it difficult to enter the sweep. For anybody else I would remind them of the contents of my running wish list, and in particular note that OXB reiterated recently that there would be 2 new AAV deals for Boston in H2, As of today there are only 4 months left in H2. The winning entry for the sweep could be today's price or OXB could sign a monster deal in the next fortnight meaning that the winning price would almost certainly be lower. It is just a bit of annual fun - like the Notting Hill carnival but with less violence. My running wish list with updates:- 1) News from AZ re covid vaccine (Roch said when not if) - DELIVERED 1st July 2022. 2) More LV deals for Oxford - DELIVERED (BMS deal expanded 21st July 2022). DELIVERED (new deal with up-front payment, confidential partner 26th July 2022). 3) New AAV deals for Boston (2 promised before year end by Roch at the full year results / Update - reiterated 16/08/2022). 4) Whatever Serum are planning under this Memorandum of understanding signed with OXB about building their footprint in the UK as mentioned by Stuart? (We can probably guess vaccine work in OxBox but they need to say). UPDATE 13th August boss of SII says in press interview that OxBox can be used for vaccine work. 5) OXB / Novartis RNS (re need for more vector for CAR-T after approval in FL would be nice). 6) Partner the in-house CAR-T drug - OXB-302 Acute Myeloid Leukaemia (they are preparing for clinical trial which Roch said we are NOT! going to do ourselves so surely they must have somebody lined up). 7) Partner something re in vivo CAR-T (is this basically T-Charge?) / confirmation from Novartis that their T-Charge program uses Lentivector. 8) One of our liver drugs partnered OXB-40X/Y/Z (early stage but somebody might want to licence). 9) News from any of our partners who are in the clinic with our tech (vague I realise but you never know as we have a lot of partners). DELIVERED (Orchard deal for LentiStable 26th July 2022). 10) Relicense the PD drug as they say they have 2 companies waiting for the legal end with Sio (I'm think this won't be quick, but you never know).
Posted at 16/8/2022 13:50 by catch007
Harry: I understand your concerns which I share. The market was clearly spooked with the Homology deal (as I was). OXB were buying purely potential (and imho overpaid Dom takes a similar view), it had a poor fund raise which exacerbated the position and expensive borrowing to complete the deal. This deal was not in keeping with the sound commercial transactions in recent history and created an unnecessary higher risk to the company in my view borne out in the share price decline. I understand full well that OXB sought to reassure investors that the deal could transform the business however until new partnerships are engaged and serious income is generated the market will and has taken a cautionary view. Hence my comment earlier that if two major partnerships are announced with Homology as indicated then the pure promise of potential becomes material fact and adds real substance. The business pipeline is strong and we have world class partners however demonstrable progress with Homology will reduce doubt and hopefully stabilise what I believe to be a seriously undervalued company now. At current share price and with $/£ situation imho there may be US suitors running the rule over OXB as an acquisition. It is very cheap at these prices! Hopefully we see a spike in share price and sooner a Homology partnership deal is announced the better. I continue to see value in OXB and will hold. GL
Oxford Biomedica share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
OXB
Oxford Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221001 20:52:39